Boston Scientific Corporation

ticker: BSX step: 01 generated: 2026-05-12 source: quick-research

Boston Scientific Corporation (BSX) — Business Overview

Business Description

Boston Scientific is the world's fastest-growing major medical device company, with FY2025 revenue of $20.1B (+19.9%) — by far the highest organic growth rate among large-cap medtech (vs. Medtronic mid-single-digit, J&J MedTech mid-single-digit, Stryker high-single-digit). Growth is led by the electrophysiology franchise anchored by FARAPULSE Pulsed Field Ablation (PFA) — the fastest-adopted cardiovascular device of the past decade — and Watchman left atrial appendage closure. BSX has positioned itself as the leader in two of medtech's fastest-growing categories: atrial fibrillation ablation and stroke prevention from afib.

Revenue Model

Two reportable segments:

• MedSurg (~$10B, growing ~+10%) — Endoscopy + urology + neuromodulation:
  • Endoscopy (~$3.5B+) — GI endoscopy, pulmonary, advanced bronchoscopy.
  • Urology (~$2.5B) — Stone management, urology services, peripheral.
  • Neuromodulation (~$1B) — Pain management, deep brain stimulation, spinal cord stim.
• Cardiovascular (~$10B+, growing ~+23%) — Three sub-franchises:
  • Cardiology (~$5B+) — Includes Watchman ($2B+ run-rate; +28% YoY).
  • Electrophysiology (~$3.4B annualized) — FARAPULSE PFA, mapping catheters, ablation.
  • Peripheral Interventions + structural heart + coronary stents.

Revenue mix is overwhelmingly recurring (consumables, single-use devices, capital-attached); EP segment is the highest-growth driver and the most concentrated competitive focus.

Products & Services

• FARAPULSE PFA: Pulsed field ablation system for atrial fibrillation; FDA-approved 2024; ~$1B+ revenue in first 12 months (fastest cardiovascular device launch in a decade). Expanded label for persistent AF (July 2025).
• Faraflex PFA + Farapoint PFA: Next-generation PFA catheters with improved workflow + mapping integration.
• Watchman FLX: Left atrial appendage closure device for AF stroke prevention; +28.4% growth FY25; $2B+ franchise.
• Endoscopy: GI navigators, hemostasis, dilation, biopsy, advanced bronchoscopy.
• Urology: Kidney stone management (LithoVue), prostate hyperplasia, men's health.
• Neuromodulation: WaveWriter SCS (spinal cord stim), Vercise DBS, Precision spinal cord stim.
• Peripheral Interventions: PAD treatment, drug-coated balloons, atherectomy, stents.
• Coronary: Drug-eluting stents (Synergy XD), balloon angioplasty.
• Cardiac Rhythm Management: Pacemakers, defibrillators (smaller share vs. MDT/ABT).
• Structural Heart: Acurate transcatheter aortic valve (TAVR — late entrant), Eluvia stent.

Customer Base & Go-to-Market

• Hospitals + cardiac centers: Electrophysiology labs (~5,000+ globally), interventional cardiology, structural heart programs.
• Ambulatory Surgery Centers (ASCs): Endoscopy + urology procedures increasingly moving to ASCs.
• GI specialists: ~16,000+ US gastroenterologists for endoscopy products.
• Pain management physicians: Neuromodulation customer base.

Geographic mix: ~60% US, ~40% international. Significant growth in Asia-Pacific + Europe for EP.

Competitive Position

BSX has emerged as the clear leader in electrophysiology PFA, having significantly outpaced Medtronic's PulseSelect, Johnson & Johnson Biosense Webster Varipulse, and Abbott (small EP presence). Structural advantages:

1. FARAPULSE first-mover PFA + best clinical data — AVANT GUARD trial showed statistical superiority over antiarrhythmic drugs; market preference firmly with Farapulse.
2. Watchman franchise compounding at 28%+ — AF treatment + stroke prevention bundle creates cross-sell with EP.
3. Bolt Medical acquisition — Intravascular lithotripsy (IVL) entry; competes with Shockwave (now Johnson & Johnson MedTech).
4. SoniVie acquisition — Renal denervation hypertension treatment platform.
5. R&D + clinical trial leadership — Multiple Phase 3 + pivotal trials simultaneously running across EP + structural heart + endoscopy.

Competitive challenges:

• Medtronic — Major Cardiac Rhythm Management franchise + Affera EP acquisition (still smaller scale).
• Johnson & Johnson MedTech (Biosense Webster + Shockwave) — Direct EP + IVL competition.
• Abbott — Newer Volt PFA entry; smaller but well-funded.
• PFA category competition increasing — Affera (Medtronic), Varipulse (J&J), PulseSelect (MDT). Market share at 35–38% currently but defensible with Faraflex / Farapoint.

Key Facts

• Founded: 1979
• Headquarters: Marlborough, Massachusetts
• Employees: ~50,000
• Exchange: NYSE
• Sector / Industry: Health Care / Medical Devices
• Market Cap: ~$165B
• FY2025 Revenue: $20.074B (+19.9% reported)
• FY2025 Organic Growth: ~+15%
• FARAPULSE Revenue (Year 1): >$1B
• Watchman Franchise Annual Run-rate: ~$2B+
• Major Recent Acquisitions: Bolt Medical (IVL), SoniVie (renal denervation), Axonics (~$3.7B, sacral neuromodulation 2024)
• Dividend: None (growth focus)
• Q4 2025 Cardiovascular Growth: +23.2%

ticker: BSX step: 04 generated: 2026-05-12 source: quick-research

Boston Scientific Corporation (BSX) — Financial Snapshot

Income Statement Summary

Segment Detail (FY2025)

FY2026 Guidance (Revised April 2026 post Q1)

Cash Flow & Balance Sheet (FY2025)

Key Ratios (approximate)

• P/E: ~34x (FY26 adjusted EPS midpoint) | EV/EBITDA: ~25x | FCF Yield: ~2.4%
• Revenue Growth (FY25): +19.9% reported, +15.8% organic
• Adjusted Operating Margin: 27.5%
• Net Debt / EBITDA: ~1.3x
• No dividend; growth-stock profile

Growth Profile

FY25 was a banner year — fastest growth in the major medtech peer group:

• Reported revenue +19.9%; organic +15.8%
• Electrophysiology (FARAPULSE) $3.4B annualized run-rate, fastest cardiovascular device launch in a decade
• Watchman LAAC franchise +28% YoY
• Adjusted operating margin expanded 80 bps to 27.5%
• Adjusted EPS +24%

FY26 guidance was revised down in April 2026 (Q1 earnings) from initial February guide:

• Organic growth: 10–11% → 6.5–8.0%
• Adjusted EPS: $3.43–3.49 → $3.34–3.41

The downward revision triggered a -18% stock reaction in Q1 2026. Concerns: PFA market share competition from Medtronic Affera + J&J Varipulse; PulseSelect FDA expansion; EP segment growth deceleration from 37% (Q4 25) to expected mid-teens FY26.

Forward Estimates

FY2026 Guide (revised April 2026):

• Net Sales: ~$22B (+10–11%)
• Organic Growth: +6.5–8.0%
• Adjusted EPS: $3.34–3.41
• FCF: ~$4B

Bull case: FARAPULSE share defends 38%+ against Medtronic Affera + J&J Varipulse; Bolt Medical IVL adds incremental growth; international EP expansion accelerates; multiple recovers to 38–40x P/E. Bear case: FARAPULSE share erosion to 25–30% over 2026–27; PFA category commoditizes; revenue growth decelerates to single-digit FY27; multiple compresses to 25x P/E. Consensus targets $130–145 vs. trading ~$105–115 (~20–35% implied upside post Q1 sell-off).

ticker: BSX step: 12 generated: 2026-05-12 source: quick-research

Boston Scientific Corporation (BSX) — Investment Catalysts & Risks

Bull Case Drivers

1. FARAPULSE — fastest cardiovascular launch in a decade — >$1B revenue in Year 1; expanded label for persistent AF (July 2025); AVANT GUARD trial showed statistical superiority over antiarrhythmic drugs. Multi-billion peak potential in $10B+ atrial fibrillation ablation market.
2. Watchman LAAC franchise +28% growth at $2B+ run-rate — Left atrial appendage closure for AF stroke prevention; multi-decade tailwind from rising AF prevalence + aging population + concomitant cross-sell with EP.
3. Next-gen PFA platform (Faraflex + Farapoint) — Workflow improvements increased PVI durability from 80.4% to 96.4%; defends share against competitor PFA entries.
4. Adjusted operating margin expanded 80 bps to 27.5% — Mix-shift toward higher-margin EP + Watchman drives operating leverage; FY26 guide +50–75 bps further expansion.
5. Cross-sell EP + Watchman = afib care ecosystem — BSX is the only major medtech with both PFA ablation + LAAC closure in the same portfolio; integrated AF care platform.
6. Bolt Medical IVL acquisition — Intravascular lithotripsy entry post-J&J's Shockwave acquisition opens new $1B+ peripheral interventions market.
7. SoniVie renal denervation — Uncontrolled hypertension platform; potential blockbuster in 2027–28.
8. Buying opportunity post-Q1 2026 sell-off (-18%) — Adjusted EPS guide cut prompted overreaction; FY26 still implies +9–11% EPS growth at >27% operating margin.

Bear Case Risks

1. FARAPULSE share erosion concerns — Q1 2026 guidance cut triggered fears that Medtronic Affera + J&J Varipulse + PulseSelect are gaining share faster than expected. Market analysts forecasting BSX PFA share at 35–38% (down from 50%+ at FARAPULSE launch).
2. PFA category commoditization — Multiple major players (MDT, J&J, ABT) with PFA platforms; pricing pressure + share fragmentation could compress margins long-term.
3. Premium valuation (~34x FY26 P/E) with growth deceleration — Organic growth guide cut from 10–11% to 6.5–8.0% creates multiple-compression risk. Stock already corrected -18% in Q1 2026 but valuation remains elevated vs. peers.
4. Acurate TAVR — late entry into mature market — Acurate Neo + Acurate Prime competing against Edwards Sapien 3 + Medtronic Evolut; uphill battle for share.
5. Coronary stents legacy decline — Synergy XD growth has plateaued; reduced importance to overall mix.
6. No dividend; capital return entirely via M&A reinvestment — Limits income investor appeal; relies on growth execution.
7. Q4 2025 guidance miss / 2026 guide revision — Operational execution concerns post the Q1 2026 EPS guide cut.
8. EP capital equipment / lab capacity constraints — Continued FARAPULSE rollout depends on cath labs adding PFA capability; potential capacity ceiling.

Upcoming Events

• Q2 2026 earnings (late July 2026): Mid-year guide check + EP growth trajectory.
• Q3 2026 earnings (late October 2026): Final guide check before FY27 setup.
• Bolt Medical / SoniVie integration milestones: Revenue contribution disclosures.
• Heart Rhythm 2026 / Heart Rhythm 2027 conferences: Major PFA clinical data readouts.
• Acurate TAVR commercial launches: Quarterly procedure volume disclosures.
• Medtronic Affera + J&J Varipulse FDA / commercial launches: Competitive monitoring.
• Annual Investor Day: Multi-year financial framework updates.

Analyst Sentiment

Consensus rating is Buy / Overweight (~75% Buy, 23% Hold, 2% Sell). Price targets cluster $130–145 vs. trading ~$105–115 (~20–35% implied upside post-Q1 sell-off). Bull case targets ~$165 on continued PFA dominance + Bolt integration; bear case ~$90 on PFA share loss + multiple compression. Morgan Stanley, Goldman, Wedbush, JPM, BMO maintain Buy/Overweight; Wells Fargo at Equal-Weight; Bernstein at Outperform.

Research Date

Generated: 2026-05-12